Hematologic and extrahematologic toxicity related to rituximab maintenance
| Toxicity . | Total, % . | Grade 1-2, % . | Grade 3-4, % . |
|---|---|---|---|
| Hematologic | |||
| Neutropenia | 31.3 | 22.8 | 8.5 |
| Thrombocytopenia | 4.6 | 4.4 | 0.2 |
| Anemia | 1.2 | 1.2 | 0 |
| Nonhematologic | |||
| Fatigue | 0.8 | 0.8 | 0 |
| Gastrointestinal toxicity | 2 | 2 | 0 |
| Hepatic toxicity | 2.2 | 2 | 0.2 |
| Encephalopathy | 0.2 | 0 | 0.2 |
| Infections | 13 | 8.4 | 4.6 |
| Infectious episodes G 3-4 | |||
| Pneumonia, n = 9 | |||
| Febrile neutropenia, n = 2 | |||
| Cutaneous infection, n = 1 | |||
| Sepsis (Staphylococcus spp), n = 1 | |||
| Cerebral abscess, n = 1 | |||
| Herpes zoster reactivation, n = 1 | |||
| Myositis, n = 1 | |||
| Appendicitis, n = 1 | |||
| Upper respiratory tract, n = 3 | |||
| Progressive multifocal leukoencephalopathy, n = 1 | |||
| Fever of unknown origin, n = 1 | |||
| Neoplasm | |||
| Lung adenocarcinoma, n = 3 | |||
| Epidermoid carcinoma, n = 1 | |||
| Low-grade urothelial carcinoma noninvasive, n = 1 | |||
| Intestinal adenocarcinoma, n = 1 |
| Toxicity . | Total, % . | Grade 1-2, % . | Grade 3-4, % . |
|---|---|---|---|
| Hematologic | |||
| Neutropenia | 31.3 | 22.8 | 8.5 |
| Thrombocytopenia | 4.6 | 4.4 | 0.2 |
| Anemia | 1.2 | 1.2 | 0 |
| Nonhematologic | |||
| Fatigue | 0.8 | 0.8 | 0 |
| Gastrointestinal toxicity | 2 | 2 | 0 |
| Hepatic toxicity | 2.2 | 2 | 0.2 |
| Encephalopathy | 0.2 | 0 | 0.2 |
| Infections | 13 | 8.4 | 4.6 |
| Infectious episodes G 3-4 | |||
| Pneumonia, n = 9 | |||
| Febrile neutropenia, n = 2 | |||
| Cutaneous infection, n = 1 | |||
| Sepsis (Staphylococcus spp), n = 1 | |||
| Cerebral abscess, n = 1 | |||
| Herpes zoster reactivation, n = 1 | |||
| Myositis, n = 1 | |||
| Appendicitis, n = 1 | |||
| Upper respiratory tract, n = 3 | |||
| Progressive multifocal leukoencephalopathy, n = 1 | |||
| Fever of unknown origin, n = 1 | |||
| Neoplasm | |||
| Lung adenocarcinoma, n = 3 | |||
| Epidermoid carcinoma, n = 1 | |||
| Low-grade urothelial carcinoma noninvasive, n = 1 | |||
| Intestinal adenocarcinoma, n = 1 |
Toxicity was based on the NCI-WG and World Health Organization classification and expressed as a percentage of the cycles administered.